About TTS Pharma
TTS Pharma is a Healthcare company based in Liverpool (United Kingdom) founded in 2012. TTS Pharma is engaged in producing high-quality, safe Cannabinoid products. It operates on a B2B2C and White Labeling model. TTS Pharma has raised $13.94 million across 3 funding rounds from investors including The North West Fund. The company has 6 employees. TTS Pharma offers products and services including CBD for Cosmetics, CBD for Food Supplements, Food and Beverages, and White Labelling. Its focus areas include Pharmaceuticals and Cannabinoid Products. Its legal entity is TTS Pharma Limited.
Company details
TTS Pharma Limited, based in the UK, is focused on the production of high-quality, safe Cannabinoid products for the ethical cannabis market. Operations are conducted within the legal frameworks of the UK and Europe, adhering to regulations set by the Home Office, Food Standards Agency, and Trading Standards. Products are developed for sectors including food, cosmetics, and nutraceuticals, with an ambition to become a leading European supplier. Advanced extraction technologies are utilized to purify components for use as Active Pharmaceutical Ingredients (API). Emphasis is placed on supply chain transparency to ensure consumer and patient trust.
- Headquarters Liverpool, United Kingdom
- Employees 6
- SectorsHealthcare
- Phone•••• ••••
- Website ttspharma.com
- Legal Name Tts Pharma Limited
- Total Equity Funding$13.94M (USD)
in 3 rounds
- Latest Funding Round$13.51M (USD), Post-IPO
Feb 2022
- Investors
- Employee Count6
Products & Services of TTS Pharma
TTS Pharma offers a comprehensive portfolio of products and services, including CBD for Cosmetics, CBD for Food Supplements, Food and Beverages, and White Labelling.
Cannabinoid products are developed for cosmetic industry applications.
Cannabinoid supplements are produced for dietary health benefits.
Cannabinoid ingredients are supplied for food and beverages.
White labelling services are offered for cannabinoid products.
Funding Insights of TTS Pharma
TTS Pharma has successfully raised a total of $13.94M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $13.51 million completed in February 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.94M
- Total Rounds 3
- Last Round Post-IPO — $13.51M
- First Round $881,821
(Dec 2012)
- Investors Count 1
All 3 funding rounds of TTS Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2022 | $13.51M | Post-IPO | – | – | – |
| May 2019 | $13.06M | Series B | – | – | – |
| Dec 2012 | $881,821 | Seed | – | – |
1 investors in total: 1 institutional.
Investors in TTS Pharma
TTS Pharma has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include The North West Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt firm | thenorthwestfund.co.uk | Warrington, United Kingdom |
Investor details for TTS Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of TTS Pharma
1 people are tracked at TTS Pharma (1 in leadership); the tracked headcount is 6.
| Name | Role | Group |
|---|---|---|
Robin Emerson | Director of Business Development and Regulatory Affairs | Leadership |
Complete people profiles for TTS Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of TTS Pharma
3 dated milestones of TTS Pharma across 10 years, from founding to its latest funding, stage changes and deals.
- Founded TTS Pharma is founded.
- Funding First funding round of $882K.
- Funding Latest funding round, Post-IPO, of $13.5M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tts Pharma
Complete news archive for TTS Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TTS Pharma
TTS Pharma was founded in 2012.
TTS Pharma is headquartered in Liverpool, United Kingdom.
TTS Pharma is a funded company, having raised a total of $13.94M across 3 funding rounds to date. The company's 1st funding round was a Seed of $881.82K, raised on Dec 2012.
TTS Pharma has 6 employees.
TTS Pharma Limited, based in the UK, is focused on the production of high-quality, safe Cannabinoid products for the ethical cannabis market. Operations are conducted within the legal frameworks of the UK and Europe, adhering to regulations set by the Home Office, Food Standards Agency, and Trading Standards. Products are developed for sectors including food, cosmetics, and nutraceuticals, with an ambition to become a leading European supplier. Advanced extraction technologies are utilized to purify components for use as Active Pharmaceutical Ingredients (API). Emphasis is placed on supply chain transparency to ensure consumer and patient trust.
TTS Pharma offers CBD for Cosmetics, CBD for Food Supplements, Food and Beverages, and White Labelling.
TTS Pharma has 1 investor. Key investors include The North West Fund.
TTS Pharma operates through Tts Pharma Limited.